Alisertib
CD30-positive Lymphoma
Eric Bernicker, MDSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the CD30-positive Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Brentuximab Vedotin Eric Bernicker, MD | Phase 1 | CC |
Same molecule, other indications
Alisertib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →